共 464 条
[1]
Slamon DJ(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177-182
[2]
Clark GM(2011)Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial Lancet Oncol 12 236-244
[3]
Wong SG(2011)Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 J Clin Oncol 29 3366-3373
[4]
Levin WJ(2005)Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J Natl Cancer Inst 97 188-194
[5]
Ullrich A(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 29 3351-3357
[6]
McGuire WL(2011)Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups J Clin Oncol 23 8331-8339
[7]
Gianni L(2005)Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer J Clin Oncol 17 935-944
[8]
Dafni U(2006)Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann Oncol 32 2100-2108
[9]
Gelber RD(2014)Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 145 143-153
[10]
Azambuja E(2014)Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) Breast Cancer Res Treat 12 54-1804